Ignite Creation Date:
2025-12-25 @ 12:29 AM
Ignite Modification Date:
2026-01-10 @ 9:38 AM
Study NCT ID:
NCT04178967
Status:
COMPLETED
Last Update Posted:
2023-05-24
First Post:
2019-11-25
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis
Sponsor:
Eli Lilly and Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-10-29
Start Date Type:
ACTUAL
Primary Completion Date:
2021-07-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-04-28
Completion Date Type:
ACTUAL
First Submit Date:
2019-11-25
First Submit QC Date:
None
Study First Post Date:
2019-11-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-07-11
Results First Submit QC Date:
None
Results First Post Date:
2022-09-16
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-04-24
Last Update Post Date:
2023-05-24
Last Update Post Date Type:
ACTUAL